AST-VAC2 is an innovative immunotherapy product that contains mature dendritic cells derived from pluripotent stem cells. These non-patient specific (allogeneic) AST-VAC2 cells are engineered to express a modified form of telomerase, a protein widely expressed in tumor cells, but rarely found in normal cells.
The modified form of telomerase permits enhanced stimulation of immune responses to the protein. The AST-VAC2 dendritic cells instruct the immune system to generate responses against telomerase which will target tumor cells.
To accelerate clinical development of AST-VAC2, Asterias has an ongoing partnership with Cancer Research UK and Cancer Research Technology, the charity’s development and commercialization arm, to execute the first clinical trial of AST-VAC2. As part of this partnership, Cancer Research UK will perform cGMP manufacture of AST-VAC2 at their Biotherapeutics Development Unit.
In preparation for cGMP production, Asterias developed the production process for AST-VAC2 to support the transfer and further scale-up in Cancer Research UK’s manufacturing facility for the Phase 1/2 clinical study.
To that end, Asterias has completed transfer of the AST-VAC2 manufacturing process information to Cancer Research UK. Cancer Research UK is now verifying and scaling up the production of AST-VAC2 in their facility in preparation for pilot and full cGMP campaigns.
Upon successful completion of AST-VAC2 production campaigns, Cancer Research UK’s Centre for Drug Development ("CDD") will submit a Clinical Trial Authorisation application to the UK regulatory authorities for a Phase 1/2 clinical trial in non-small cell lung cancer, which will be sponsored, managed and funded by CDD.
The clinical trial will examine the safety, immunogenicity and activity of AST-VAC2 and position the immunotherapy to be tested for numerous clinical indications.
Asterias CEO Pedro Lichtinger said: "Transfer of the manufacturing process for AST-VAC2 marks an important milestone in our partnership with Cancer Research UK and is a critical step towards initiating the first clinical trial of AST-VAC2.
"The program with Cancer Research UK will assess the safety and activity of AST-VAC2 and serve as a foundation for further clinical development in lung and other cancers."
Asterias president of R&D and chief scientific officer Jane Lebkowski said: "The design of AST-VAC2 affords three unique properties to this dendritic cell immunotherapy.
"Being produced from pluripotent stem cells, AST-VAC2 can be manufactured at batch-scale and be available on-demand for patient use. Second, the telomerase protein in AST-VAC2 is specifically engineered to target the two major pathways stimulating T cell immune responses, inducing more robust and durable cellular immune responses to telomerase. Lastly, the non-patient specific, allogeneic, nature of AST-VAC2 could potentially provide signals to further amplify immune responses."
"Based on its mode of action, AST-VAC2 is likely to be synergistic with immune checkpoint inhibitors and other adoptive immunotherapies that are being used for treatment now," stated Katy Spink Ph.D., Chief Operating Officer of Asterias. "The combination of the immunostimulatory activity of AST-VAC2 with the drugs that downregulate inhibitors of immune responses could provide a very powerful tool for the treatment of multiple cancers."
Cancer Research UK’s director of drug development Nigel Blackburn said: "This drug could potentially treat most tumour types as it targets the telomerase protein – which is faulty in 95 per cent of all cancers. The treatment’s design means it could also boost the effects of other immunotherapies and be used in combination.
"Lung cancer is the biggest cancer killer so we desperately need to find new treatments for the disease. And we’re pleased to be working with Asterias Biotherapeutics to develop this new treatment and to test it in clinical trials for non-small cell lung cancer for the first time."